About

svelte-logo

In the News

Press Releases

October 24, 2016

Svelte Medical Systems Announces CE Mark Certification of DIRECT RX

DIRECT RX Combines a New Class of Bioresorbable Drug Coating, Highly Conformable Stent Design and Proprietary Balloon Technology to Provide a Workhorse Coronary Drug-Eluting Stent (DES) Rapid-Exchange System Designed to Enhance Direct Stenting.

Read More

June 7, 2016

Robert Fischell, Co-Founder of Svelte Medical Systems, Honored at White House

Robert Fischell, a holder of more than 200 US and foreign medical patents, receives the National Medal of Technology and Innovation from President Obama.

Read More

January 19, 2016

Svelte Medical Systems Announces European Launch of SLENDER IDS

The World’s First Drug-Eluting Coronary Stent-on-a-Wire Integrated Delivery System Downsizes Catheters, Facilitates Transradial Intervention (TRI) and Maximizes Procedural Efficiency.

Read More

December 15, 2015

Svelte Medical Systems Announces CE Mark Certification of SLENDER IDS

The World’s First Drug-Eluting Coronary Stent-on-a-Wire Integrated Delivery System Downsizes Catheters, Facilitates Transradial Intervention (TRI) and Maximizes Procedural Efficiency.

Read More

May 20, 2015

Svelte Medical Systems Announces Updates to Clinical Program

World’s First Drug-Eluting Coronary Stent-on-a-Wire Demonstrates Sustained Clinical Results, 0% Stent Thrombosis in DIRECT II Randomized, Controlled Study; Plans for IDE Study Revealed.

Read More

March 19, 2015

Svelte Medical Systems Secures Financing; Richard Dakers Joins Board

All-insider round of investment funds ongoing operations and upcoming commercial activities in Europe. Richard Dakers of the West Health Investment Fund joins the company Board of Directors.

Read More

February 12, 2015

Svelte Medical Systems and ASAHI INTECC Announce Manufacturing and Co-Branding Agreements

Collaboration Features Latest ASAHI Technology in Design, Development and Supply of Core Wire & Coil Assembly for the Svelte Drug-Eluting Coronary Stent Fixed Wire Integrated Delivery System.

Read More

September 18, 2014

World’s First Integrated Delivery System Meets All Endpoints in the DIRECT II Randomized, Controlled Drug-Eluting Coronary Stent Study

Washington, D.C. – Svelte Medical Systems today reported that its drug-eluting coronary stent Integrated Delivery System (IDS), a new approach to Percutaneous Coronary Intervention (PCI) and the first advance in coronary stent delivery in nearly 20-years, met all DIRECT II study 6-month angiographic and clinical endpoints.

Read More

May 29, 2014

Svelte Medical Systems Announces Completion of 6-Month Follow-up in the DIRECT II Drug-Eluting Stent Study

New Providence, N.J. – Svelte Medical Systems today announced completion of primary endpoint 6-month follow-up in DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioresorbable drug Carrier Technology), a prospective, randomized, multi-center clinical study comparing the safety and efficacy of the Svelte drug-eluting coronary stent Integrated Delivery System (IDS) to Medtronic’s Resolute Integrity™ drug-eluting stent.

Read More

March 10, 2014

West Health Investment Fund Joins Svelte Medical Systems Private Financing as Major Investor

New Providence, NJ – Svelte Medical Systems today announced that the Gary and Mary West Health Investment Fund has joined CNF Investments and New Science Ventures as major investors in the company.

Read More

 

CAUTION: The law restricts SLENDER IDS to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. SLENDER IDS is CE approved. DIRECT RX is an investigational device not approved for commercial use. SLENDER IDS and DIRECT RX are not available for sale in the US.